article · BioMed Research International
Evaluation of an eighty percent methanol extract from Pithecellobium dulce seeds reveals notable antibacterial activity against multi-drug-resistant clinical bacterial strains. Chemical profiling identified D-turanose as the predominant component, followed by hexadecanoic acid, indole-1-acetic acid, inositol, and octadecanoic acid. Laboratory testing showed that the extract inhibited the growth of Acinetobacter baumannii, Staphylococcus aureus, and Escherichia coli, with minimum inhibitory concentrations ranging between 233 and 300 milligrams per millilitre. Computational molecular docking demonstrated that both turanose and inositol exhibited favourable binding affinities when interacting with two specific Staphylococcus aureus target macromolecules. In addition, several of the identified compounds displayed desirable predicted bioavailability characteristics. These combined in silico and in vitro findings highlight the potential of Pithecellobium dulce seed extract as a natural starting material for developing therapeutic treatments against resistant bacterial pathogens.
Multi-drug-resistant bacteria represent an escalating global health threat as standard antibiotics continue to lose efficacy against common clinical infections. Discovering active bioactive agents from plant sources provides important avenues for drug discovery. Demonstrating that seed extracts from Pithecellobium dulce can inhibit resistant pathogens while possessing favourable bioavailability profiles offers an encouraging starting point for alternative antimicrobial strategies.
This work could assist pharmaceutical researchers and drug discovery teams seeking plant-derived leads against resistant bacterial strains. The findings represent early-stage research based on in silico screening and basic in vitro testing. Substantial progression will be required, including compound purification, toxicity profiling, in vivo validation, and formulation design, before these molecules could form part of a viable clinical product or commercial pipeline.
AI-generated from the published abstract. Always read the original work before citing.
Clinical multi‐drug‐resistant bacteria continue to be a serious health problem. Plant‐derived molecules are an important source of bioactive compounds to counteract these pathogenic bacteria. In this paper, we studied the chemical composition of the methanol (80%) extract from Pithecellobium dulce seed (Hail, Saudi Arabia) and its ability to inhibit the growth of clinically relevant multi‐drug‐resistant bacteria. Molecular docking analysis was performed to predict the best compounds with low binding energy and high affinity to interact with two Staphylococcus aureus receptors. Data showed that P. dulce extract is a rich source of D‐turanose (55.82%), hexadecanoic acid (11.56%), indole‐1‐acetic acid (11.42%), inositol (5.78%), and octadecanoic acid (4.36%). The obtained extract showed antibacterial activity towards tested clinical bacterial strains with MIC values ranging from 233 mg/mL for Acinetobacter baumannii to 300 mg/mL for S. aureus and Escherichia coli . Turanose interaction has resulted in ‐7.4 and ‐6.6 kcal/mol for 1JIJ and 2XCT macromolecules, while inositol showed energy values (−7.2 and −5.4 kcal/mol) for the same receptors. Multiple identified compounds showed desirable bioavailability properties indicating its great potential therapeutic use in human. Overall, current investigation highlights the possible use of P. dulce extract as a valuable source for drug development against pathogenic drug‐resistant bacteria.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1155/2023/2848198
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
